Unique molecular features in high-risk histology endometrial cancers

Pooja Pandita, Xiyin Wang, Devin E. Jones, Kaitlyn Collins, Shannon M. Hawkins

Research output: Contribution to journalReview article

Abstract

Endometrial cancer is the most common gynecologic malignancy in the United States and the sixth most common cancer in women worldwide. Fortunately, most women who develop endometrial cancer have low-grade early-stage endometrioid carcinomas, and simple hysterectomy is curative. Unfortunately, 15% of women with endometrial cancer will develop high-risk histologic tumors including uterine carcinosarcoma or high-grade endometrioid, clear cell, or serous carcinomas. These high-risk histologic tumors account for more than 50% of deaths from this disease. In this review, we will highlight the biologic differences between low-and high-risk carcinomas with a focus on the cell of origin, early precursor lesions including atrophic and proliferative endometrium, and the potential role of stem cells. We will discuss treatment, including standard of care therapy, hormonal therapy, and precision medicine-based or targeted molecular therapies. We will also discuss the impact and need for model systems. The molecular underpinnings behind this high death to incidence ratio are important to understand and improve outcomes.

Original languageEnglish (US)
Article number1665
JournalCancers
Volume11
Issue number11
DOIs
StatePublished - Nov 2019

Fingerprint

Endometrial Neoplasms
Histology
Neoplasms
Molecular Targeted Therapy
Endometrioid Carcinoma
Carcinoma
Carcinosarcoma
Precision Medicine
Standard of Care
Endometrium
Hysterectomy
Stem Cells
Therapeutics
Incidence

Keywords

  • Endometrial cancer
  • High-risk histology
  • Hormone therapy
  • Molecular features
  • Precision medicine
  • Stem cells
  • Treatment
  • Uterine cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Unique molecular features in high-risk histology endometrial cancers. / Pandita, Pooja; Wang, Xiyin; Jones, Devin E.; Collins, Kaitlyn; Hawkins, Shannon M.

In: Cancers, Vol. 11, No. 11, 1665, 11.2019.

Research output: Contribution to journalReview article

Pandita, Pooja ; Wang, Xiyin ; Jones, Devin E. ; Collins, Kaitlyn ; Hawkins, Shannon M. / Unique molecular features in high-risk histology endometrial cancers. In: Cancers. 2019 ; Vol. 11, No. 11.
@article{d361c623a1434c6f9e8c8e2cc2f8cb31,
title = "Unique molecular features in high-risk histology endometrial cancers",
abstract = "Endometrial cancer is the most common gynecologic malignancy in the United States and the sixth most common cancer in women worldwide. Fortunately, most women who develop endometrial cancer have low-grade early-stage endometrioid carcinomas, and simple hysterectomy is curative. Unfortunately, 15{\%} of women with endometrial cancer will develop high-risk histologic tumors including uterine carcinosarcoma or high-grade endometrioid, clear cell, or serous carcinomas. These high-risk histologic tumors account for more than 50{\%} of deaths from this disease. In this review, we will highlight the biologic differences between low-and high-risk carcinomas with a focus on the cell of origin, early precursor lesions including atrophic and proliferative endometrium, and the potential role of stem cells. We will discuss treatment, including standard of care therapy, hormonal therapy, and precision medicine-based or targeted molecular therapies. We will also discuss the impact and need for model systems. The molecular underpinnings behind this high death to incidence ratio are important to understand and improve outcomes.",
keywords = "Endometrial cancer, High-risk histology, Hormone therapy, Molecular features, Precision medicine, Stem cells, Treatment, Uterine cancer",
author = "Pooja Pandita and Xiyin Wang and Jones, {Devin E.} and Kaitlyn Collins and Hawkins, {Shannon M.}",
year = "2019",
month = "11",
doi = "10.3390/cancers11111665",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - Unique molecular features in high-risk histology endometrial cancers

AU - Pandita, Pooja

AU - Wang, Xiyin

AU - Jones, Devin E.

AU - Collins, Kaitlyn

AU - Hawkins, Shannon M.

PY - 2019/11

Y1 - 2019/11

N2 - Endometrial cancer is the most common gynecologic malignancy in the United States and the sixth most common cancer in women worldwide. Fortunately, most women who develop endometrial cancer have low-grade early-stage endometrioid carcinomas, and simple hysterectomy is curative. Unfortunately, 15% of women with endometrial cancer will develop high-risk histologic tumors including uterine carcinosarcoma or high-grade endometrioid, clear cell, or serous carcinomas. These high-risk histologic tumors account for more than 50% of deaths from this disease. In this review, we will highlight the biologic differences between low-and high-risk carcinomas with a focus on the cell of origin, early precursor lesions including atrophic and proliferative endometrium, and the potential role of stem cells. We will discuss treatment, including standard of care therapy, hormonal therapy, and precision medicine-based or targeted molecular therapies. We will also discuss the impact and need for model systems. The molecular underpinnings behind this high death to incidence ratio are important to understand and improve outcomes.

AB - Endometrial cancer is the most common gynecologic malignancy in the United States and the sixth most common cancer in women worldwide. Fortunately, most women who develop endometrial cancer have low-grade early-stage endometrioid carcinomas, and simple hysterectomy is curative. Unfortunately, 15% of women with endometrial cancer will develop high-risk histologic tumors including uterine carcinosarcoma or high-grade endometrioid, clear cell, or serous carcinomas. These high-risk histologic tumors account for more than 50% of deaths from this disease. In this review, we will highlight the biologic differences between low-and high-risk carcinomas with a focus on the cell of origin, early precursor lesions including atrophic and proliferative endometrium, and the potential role of stem cells. We will discuss treatment, including standard of care therapy, hormonal therapy, and precision medicine-based or targeted molecular therapies. We will also discuss the impact and need for model systems. The molecular underpinnings behind this high death to incidence ratio are important to understand and improve outcomes.

KW - Endometrial cancer

KW - High-risk histology

KW - Hormone therapy

KW - Molecular features

KW - Precision medicine

KW - Stem cells

KW - Treatment

KW - Uterine cancer

UR - http://www.scopus.com/inward/record.url?scp=85074376911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074376911&partnerID=8YFLogxK

U2 - 10.3390/cancers11111665

DO - 10.3390/cancers11111665

M3 - Review article

AN - SCOPUS:85074376911

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 11

M1 - 1665

ER -